04-JAN-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3858 311 191 96 25 5 02/06/2019 464 182
Screened at PD     1387 147 107 58 12 3      
Pre-Screened prior to PD     2454 147 73 32 10 1      
Treatment-naive     17 17 11 6 3 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     520 25 13 7 1 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2058 305 140 75 23 2      
Screened at PD     1159 168 104 57 18 2      
Pre-Screened prior to PD     827 117 25 11 2 0      
Treatment-naive     16 16 10 6 3 0      
After PD on a Lung_MAP Sub-Study     56 4 1 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     270 270 122 64 18 1      
S1900G     34 7 3 2 1 1      
S1900J     15 7 3 2 1 0      
S1900K     29 21 12 7 3 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     567 72 56 30 12 2      
Initial sub-study registrations     555 72 56 30 12 2      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 49 49 45 24 10 1 05/22/2025 332 111
Docetaxel plus Ramucirumab Y   25 25 23 12 4 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   24 24 22 12 6 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 23 6 2 1 0 0 05/05/2023 335 109
Capmatinib + Osimertinib + Ramucirumab Y   13 5 2 1 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 2 1 1 0 0 11/19/2024 249 83
Amivantamab Hyaluronidase Y   3 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 18 15 8 4 2 1 08/08/2024 266 89
Tepotinib + Ramucirumab Y   11 9 4 2 1 1      
Tepotinib Y   7 6 4 2 1 0